Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

(2010) Yue Wang et al.   CANCER LETTERS

DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma

(2010) K. T. Kuo et al.   CLINICAL CANCER RESEARCH

Expression profiling of 22 genes involved in the PI3K–AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations

(2010) Lluis Catasus et al.   MODERN PATHOLOGY

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

(2010) Michael H Roh et al.   MODERN PATHOLOGY

Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway

(2009) E.-S. A. Arafa et al.   CANCER RESEARCH

XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma

(2009) Jia-jia Ma et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Cleaved caspase-3 and nuclear factor-κB p65 are prognostic factors in metastatic serous ovarian carcinoma

(2009) Lilach Kleinberg et al.   HUMAN PATHOLOGY

Concomitant PI3K–AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis

(2009) Lluis Catasus et al.   MODERN PATHOLOGY

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH